Table 2.

Crude and adjusted odds ratios for serious infections across offspring in different exposure groups (n = 8507).

Exposure Group	Crude ORs (95% CI)	Adjusted ORs (95% CI)
No drug exposure	Ref	Ref
Vedolizumab	0.76 (0.11-5.52)	0.87 (0.13-6.15)
TNFi	0.96 (0.66-1.38)	0.95 (0.61-1.40)
Other biologic (ustekinumab, natalizumab)	2.11 (0.31-14.2)	2.05 (0.29-14.5)
Traditional immunosuppressants	0.80 (0.58-1.12)	0.78 (0.55-1.09)